Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer
Agin-Liebes, G. I., Bogenschutz, M. P., Griffiths, R. R., Grinband, J., Kinslow, C. J., Petridis, P. D., Ross, S., Zeifman, R. J.
This pooled analysis of two Phase II RCTs (n=79) evaluates psilocybin-assisted psychotherapy (PAP/PAT) for cancer-related distress. PAT significantly improves anxiety, depression, interpersonal sensitivity, hostility, obsession-compulsion, and somatization without inducing lasting phobia, paranoia, or psychosis.
Abstract
Psilocybin-assisted psychotherapy (PAP) has shown promise in treating mood and anxiety disorders in patients with cancer. However, patients with cancer often suffer from more than just depression and anxiety, and so far, PAP’s effect on other psychiatric symptoms remains largely unknown. To address this gap, we pooled previously unpublished data from two phase II, randomized, placebo-controlled crossover trials involving 79 participants with cancer-related distress and analyzed PAP’s effect on 9 psychiatric symptom dimensions: anxiety, depression, interpersonal sensitivity, hostility, obsession-compulsion, somatization, phobia, paranoia and psychosis. PAP significantly improved anxiety, depression, interpersonal sensitivity, hostility, obsession-compulsion and somatization without inducing any lasting phobia, paranoia or psychosis. Clinical improvements were consistent between trials. Together, our findings suggest that PAP has the potential to be a comprehensive mental health treatment for patients with cancer.